Molecular Partners AG American Depositary Shares (MOLN)
Summary
Molecular Partners AG (MOLN) Discusses Clinical Imaging and Dosimetry Data for DLL3 Targeting Radiotherapeutic MPO712 Transcript
Molecular Partners AG (MOLN) Discusses Clinical Imaging and Dosimetry Data for DLL3 Targeting Radiotherapeutic MPO712 Transcript
Molecular Partners AG (MOLN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Molecular Partners AG (MOLN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Molecular Partners AG (MOLN) Discusses First Human Imaging Data and Clinical Plans for MP0712 Radiotherapy Program Transcript
Molecular Partners AG ( MOLN ) Discusses First Human Imaging Data and Clinical Plans for MP0712 Radiotherapy Program November 12, 2025 10:00 AM EST Company Participants Patrick Amstutz - Co-Founder, CEO, Member of Management Board & Director Daniel Steiner - Senior Vice President of Research & Technology Philippe Legenne - Chief Medical Officer & Member of the Management Board Michael Stumpp - Co-Founder, Executive VP of Projects & Member of Management Board Conference Call Participants Jonathan Chang - Leerink Partners LLC, Research Division Michael Nedelcovych - TD Cowen, Research Division Presentation Operator Good day, and thank you for standing by. Welcome to the MP0712 update call.
Molecular Partners AG American Depositary Shares Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| RB Robert Burns HC Wainwright & Co. | 1,328.68 | $5,616.59 | $5,460.89 | -$155.7 | -2.77% |
Molecular Partners AG American Depositary Shares (MOLN) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Molecular Partners AG American Depositary Shares ever had a stock split?
Molecular Partners AG American Depositary Shares Profile
| Biotechnology Industry | Healthcare Sector | Patrick Amstutz CEO | NASDAQ (NGS) Exchange | 60853G106 CUSIP |
| CH Country | 158 Employees | - Last Dividend | - Last Split | 16 Jun 2021 IPO Date |
Overview
Molecular Partners AG is a pioneering clinical-stage biopharmaceutical company based in Schlieren, Switzerland, specializing in the development of therapeutic proteins for the treatment of diseases across oncology and virology. Leveraging its proprietary designed ankyrin repeat proteins (DARPin) technology, the company focuses on engineering highly specific and versatile drug candidates with potential applications in various therapeutic areas. Since its inception in 2004, Molecular Partners AG has established both license and research collaboration agreements with notable industry giants such as Novartis AG, and a collaboration agreement with Orano Med SAS, highlighting its strategic partnerships aimed at advancing DARPin-conjugated radioligand therapies and novel Radio-DARPin therapeutics.
Products and Services
- MP0317 (CD40 Agonist)
- MP0533 (Tetra-specific T cell-engaging DARPin)
- Switch-DARPin Platform
- Radio-DARPin Therapy (RDT) Platform
Currently in Phase I clinical trials, MP0317 is designed as a CD40 agonist that aims to activate immune cells within the tumor microenvironment. This therapeutic approach specifically targets the fibroblast activation protein, proposing a novel strategy to stimulate an immune response against cancer cells.
A groundbreaking tetra-specific T cell-engaging DARPin candidate, MP0533 is being developed for the treatment of acute myeloid leukemia. This innovative therapy combines multiple specificities to enhance its targeting and efficacy against leukemia cells, showcasing the company's cutting-edge approach to cancer treatment.
The Switch-DARPin platform represents a new frontier in multispecific and conditional immune cell activation. This program, specifically the cKIT x CD16a x CD47 Switch-DARPin, is engineered to selectively activate immune cells in the presence of targeted conditions, offering a more controlled therapeutic approach.
Molecular Partners AG's RDT platform is a novel system devised for the precise and selective delivery of radioactive payloads to solid tumors. This innovative technology embodies the company’s commitment to developing advanced therapeutic options that offer targeted treatment solutions with potentially reduced side effects.
